期刊文献+

儿童淋巴瘤病人贫血状况回顾性调查评估 被引量:1

Results of a large retrospective survey: defining the prevalence, incidence and prognostic stratification of anaemia in children lymphoma patient
下载PDF
导出
摘要 目的本研究探讨儿童淋巴瘤病人贫血患病率、发病率及治疗模式,确定发生贫血的危险因素。方法回顾性分析318例淋巴瘤患儿的病史及随访资料,包括年龄、性别、肿瘤类型、肿瘤及贫血的治疗方式,WHO体力状态等,并以血红蛋白水平为基础进行统计检验。结果贫血患病率为52.75%。血红蛋白水平与WHO得分明显相关(P<0.001)。在调查过程中贫血发病率为38.8%,年龄越小发病率越高;仅47.3%的病人在调查过程中接受了贫血的治疗。在开始治疗时总体血红蛋白最低点水平为89g/L,与贫血有关的危险因素有初始血红蛋白水平低、女性、抵抗性疾病以及铂类药物化疗等。结论淋巴瘤病人贫血患病率及发病率高,生活质量较差,应重视其治疗及危险因素的确定。 Objective To determine the prevalence, incidence of anaemia and its treatment in children with non-Hodgkin s lymphoma (NHL), and Hodgkin s disease (HD), further assess its predictive factors. Methods Data for a total of 318 patients were analyzed; variables including age, gender, tumor type/stage, cancer and anemia therapy, WHO performance status were subject to statistic analysis based on hemoglobin (Hb) levels. Results Anemia prevalence rate at enrollment was 52.75% and Hb levels correlated significantly ...
出处 《临床小儿外科杂志》 CAS 2008年第1期15-19,共5页 Journal of Clinical Pediatric Surgery
基金 国家自然科学基金重点项目资助项目(项目号:30330590)
关键词 淋巴瘤/并发症 贫血 Lymphoma/CO Anemia
  • 相关文献

参考文献11

  • 1[1]Birgegard G,Gascon P,Ludwig H.Evaluation of anaemia in patients with multiple myeloma and lymphoma:findings of the European CANCER ANAEMIA SURVEY[J].Eur J Haematol,2006,77(5):378-386.
  • 2[2]Curt G,Johnston PG.Cancer fatigue:the way forward[J].Oncologist,2003,8(1):27-30.
  • 3[3]Caro JJ,Salas M,Ward A,et al.Anemia as an independent prognostic factor for survival in patients with cancer:a systemic,quantitative review[J].Cancer,2001,91(12):2214-2221.
  • 4[4]Barrett-Lee PJ,Ludwig H,Birgegard G,et al.European Cancer Anaemia Survey Advisory Board and Participanting Centers.Independent risk factors for anemia in cancer patients receiving chemotherapy:results from the European Cancer Anaemia Survey[J].Oncology,2006,70(1):34-48.
  • 5[5]Sieniawski M,Franklin J,Nogova L,et al.Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favomble Hodgkin's lymphoma[J].J Clin Oncol,2007,25(15):2000-2005.
  • 6[6]Birgegard G,Aapro MS,Bokemeyer C,et al.Cancer-related anemia:pathogenesis,prevalence and treatment[J].Oncology,2005,68(1):3-11.
  • 7[7]Ludwig H,Van Belle S,Barrett-Lee P,et al.The European Cancer Anaemia Survey(ECAS):a large,multinational,prospective survey defining the prevalence,incidence,and treatment of anaemia in cancer patients[J].Eur J Cancer,2004,40(15):2293-2306.
  • 8[8]Henry DH,Dahl NV,Auerbach M,et al.Intravenous ferric gluconate significantly impmves respense to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy[J].Oncologist,2007,12(2):231-242.
  • 9[9]Osterborg A,Steegmann JL,Hellmann A,et al.Phase Ⅱ study of three dose levels of continuous erythropoietin receptor activator(C.E.R.A.)in anaemic patients with aggressive nonHodgkin's lymphoma receiving combination chemotherapy[J].Br J Haematol,2007,136(5):736-744.
  • 10[10]Rizzo JD,Lichtin AE,Woolf SH,et al.Use of epoetin in patients with cancer:evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology[J].Blood,2002,100(7):2303-2320.

同被引文献1

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部